BioSpace News Archive

Epigen Biosciences, Inc. announced today that it has entered into a collaboration agreement with Novo Nordisk...

Study published in Cell demonstrates causal link between seizure susceptibility and the microbiome, identifies gut bacteria that confer anti-seizure effects

Sproutly Inc. (“Sproutly” or the “Company”) is pleased to announce that it has entered into non-binding letters of intent (the “Letters of Intent”) to acquire: 1) Infusion Biosciences Canada Inc., a biotech company possessing the rights to Infusion Biosciences Inc.’s (“Infusion Biosciences”) APP Technology (defined below) for specific jurisdictions;

EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot® Adhesive manufactured by EndoClot Plus Co., Ltd. located in Suzhou, China.

Spinal Elements, a spine technology company, today announced the release of its Clutch interspinous process device.

Drug Substance produced in AGC Biologics’ facility in Bothell, Washington

Today, DotLab announces that a new longitudinal study has been initiated at the Yale School of Medicine to validate its non-invasive blood and saliva tests for endometriosis.

DSUVIA PDUFA date set for November 3, 2018

The research was directed by two of Antibe’s founders, Drs. Andre Buret and John Wallace.

EVIO Inc. (“EVIO” or the “Company”), (OTCQB: EVIO), a leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, is excited to announce the launch of its EVIO Biosciences Division.